- Opinion
- [Reporter's View] US tariffs…variable that must be faced
- by Whang, byung-woo Jul 11, 2025 06:12am
- Tension is growing in the domestic pharmaceutical and biotech industry as President Donald Trump recently announced the potential imposition of tariffs on imported pharmaceuticals. If the tariff hike is imposed, it is expected to directly impact not only the procurement costs of raw materials and sub-materials for Korean companies but als
- Opinion
- [Reporter’s View] Time to verify K-radiopharmaceuticals
- by Son, Hyung Min Jul 10, 2025 06:09am
- Radiopharmaceuticals are special preparations that combine drugs with radioactive isotopes for diagnostic or therapeutic use. In particular, radioligand therapy (RLT), which delivers radiation directly to tumor cells, is known for its high precision, being referred to as "moving radiation surgery." As beta particle-based radioligand thera
- Opinion
- [Reporter's View] The revision of the Commercial Act
- by Kim, Jin-Gu Jul 9, 2025 06:08am
- The bill on revising the Commercial Act has passed the National Assembly. The bill expands the fiduciary duty of directors to include not only the “company” but also “shareholders,” mandates the introduction of electronic shareholder meetings for listed companies with assets of KRW 2 trillion or more, and changes the title of “outside d
- Opinion
- [Reporter’s View] NHI finances and reimb expansions
- by Lee, Jeong-Hwan Jul 4, 2025 06:06am
- Striking a balance between improving the financial sustainability of the national health insurance system and enhancing patient access to drugs for rare and intractable diseases is a national issue. The two issues that repeatedly come into conflict have long occupied the attention of all political parties in their search for solutions, ye
- Opinion
- [Reporter’s View] Doctors agree Korea’s reimb is too slow
- by Eo, Yun-Ho Jul 2, 2025 06:09am
- Even prescribing physicians believe that the pace of new drug reimbursement listing in Korea is too slow. This is an issue not only for doctors or patients, but obviously for pharmaceutical companies as well. Recently, the Korean Research-based Pharmaceutical Industry Association (KRPIA) released the results of a survey of 100 medical pro
- Opinion
- [Reporter's View] Divisional restructuring needed
- by Lee, Hye-Kyung Jun 30, 2025 06:06am
- During his candidacy, President Lee Jae-myung pledged to designate the biotech industry as a cutting-edge sector and build it as the future growth engine, aiming to position South Korea as one of the world's five strongest biotech countries. Based on an analysis that the previous government was short on investment in the pharmaceutical and bi
- Opinion
- [Reporter's View] For local gov't seeking biotech diplomacy
- by Whang, byung-woo Jun 30, 2025 06:05am
- 'BIO USA,' held in Boston, U.S., is the world's largest biotech industry conference. Notably, this year's conference was attended by officials from Korea's local government. The attending officials aimed to promote local biotech clusters and seek potential investment partners. Through this event, they intended to establish a gamer-changer
- Opinion
- [Reporter's View] Silent efforts pay off in the market
- by Son, Hyung Min Jun 25, 2025 06:02am
- In the first half of this year, South Korean pharmaceutical and biotech companies achieved notable success through technology exports. A series of major licensing deals were signed based on the companies’ innovative drug development platforms and clinical trial results the companies steadily developed and accumulated over the years. In A
- Opinion
- [Reporter's View] Telemedicine in a 5-sided tug-of-war
- by Lee, Jeong-Hwan Jun 19, 2025 06:02am
- With the election and inauguration of President Lee Jae-Myung, the Democratic Party of Korea, which successfully changed the administration, submitted a bill to revise the Medical Service Act that narrows the scope of telemedicine’s initial consultation in the current pilot program to the National Assembly. As a result, the eyes of the
- Opinion
- [Desk View] Disclosing drug reimb info must be done properly
- by Lee, Tak-Sun Jun 18, 2025 06:00am
- Due to concerns about the non-transparency of the selection process for medicinal product reimbursement, the Health Insurance Review & Assessment Service (HIRA) and the National Health Insurance Service (NHIS) are disclosing partial processes and candidates. HIRA discloses, through press releases, the review results from the Cancer Drug Re
